Novel Agent Set for Unique Clinical Test in Inflammatory Breast Cancer
12/13/2013
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.
Exercise protects against aggressive breast cancer in black women
12/13/2013
A nearly 20-year observational study involving more than 44,700 black women nationwide found that regular vigorous exercise offers significant protection against development of an aggressive subtype of breast cancer. The findings from the Black Women's Health Study were presented at the 2013 San Antonio Breast Cancer Symposium.
Event-free and overall survival results from NeoALTTO trial
12/13/2013
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial were presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Identifying breast cancer patients most likely to benefit from trastuzumab
12/13/2013
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response. This is a first. Nrp1 may provide an important hub for the development of new therapies against cancer.
Patients with non-Hodgkin lymphomas resistant to treatment benefit from drug-antibody pair
12/12/2013
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
Pediatric leukemia patients benefit from less painful drug delivery
12/12/2013
Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.Researchers looked at the four-year, event-free survival and toxicity of E.
Growing umbilical cord blood stem cells in lab before transplant boosts leukemia, lymphoma survival
12/12/2013
Donated umbilical cord blood contains stem cells that can save the lives of patients with leukemia, lymphoma and other blood cancers.Now a study lead by a Loyola University Medical Center oncologist has found that growing cord blood stem cells in a laboratory before transplanting them into patients significantly improves survival.
Action could help millions of Americans exposed to silica at work
12/12/2013
A new review highlights new developments in understanding the health effects of silica, and calls for action to reduce illness and death from silica exposure at work, including stronger regulations, heightened awareness and prevention, and increased attention to early detection of silicosis and lung cancer using low dose CT scanning.
Finnish research unveils novel cancer cell DNA damage repair mechanism
12/12/2013
Cancer cells have an exceptional ability to repair damage to their DNA caused during uncontrolled cell division. Scientists have now unveiled a novel piece of the puzzle of cancer cell DNA repair mechanisms that explain the mechanistic changes in the genetic code of cancer cells.